Tuesday, April 29, 2025

Latest

KetamineOne Adds Two Texas Locations To Clinical Network

KetamineOne Capital (NEO: MEDI) has continued to expand its presence across North America. The firm this morning announced that it has entered into a letter of intent for two additional ketamine clinics, which are to be located in Texas.

The additional footprint south of the border is to come via an arranged partnership with Illumma LLC, whom has a clinic in Austin as well as Bee Cave, Texas. The arrangement will bring the firms total stateside footprint to six clinics.

The two clinics from Illumma fit well with KetamineOne’s current model, in that they already offer ketamine infusion, which focuses on mental health, mood disorders, and chronic pain. The locations are to be jointed supported via KetamineOne’s existing clinical network.

“Illumma’s two existing clinics have already contributed to the improved mental health of their patients by applying innovative ketamine infusion therapies like those offered in Ketamine One’s clinical network. We expect that this arrangement will attract other partnerships or even acquisition targets, and yield further expansion opportunities across the United States,” commented Adam Deffett, the interim CEO of KetamineOne.

Under the terms of the arrangement, KetamineOne is to pay total consideration of $0.98 million for the partnership. Payment is to be split equally between common share and cash, with $350,000 of the cash consideration to be allocated for the development of additional clinics.

The addition of further clinics to KetamineOne’s network follows a major development announced last week, wherein the firm is to deploy Cognetivity Neuroscience’s (CSE: CGN) cognitive assessment tool across its North American network for use in monitoring both treatment-resistant depression as well as PTSD.

KetamineOne Capital last traded at $1.35 on the Neo Exchange.


FULL DISCLOSURE: KetamineOne is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover KetamineOne on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Leave a Reply

Video Articles

Bell Q3 Earnings: Massive Impairments. Guidance Cuts. A Mess.

Alamos Gold Q3: Record Revenue & Production Amid Rising Costs

The Junior Mining Market Is Back

Recommended

Germany Looks To Modernize Military Recruitment But Stops Short of Conscription

First Majestic Silver Posts Topline Revenue Of $146.1 Million In Q3 2024

Related News

KetamineOne Expands Veteran Clinics With Four New Locations Across Canada

KetamineOne Capital (NEO: MEDI) is expanding its current offerings for veteran-focused multidisciplinary clinics. The company...

Monday, August 30, 2021, 08:10:22 AM

KetamineOne Announces Two Studies Focused On PTSD, Depression

KetamineOne Capital (NEO: MEDI) has officially begun its research programs. The firm this morning announced...

Thursday, October 14, 2021, 08:55:13 AM

KetamineOne Expands Offerings Of IRP Health With New Partnership

KetamineOne Capital (NEO: MEDI) is evidently looking to expanding its service offerings. The firm this...

Tuesday, September 14, 2021, 08:42:53 AM

KetamineOne Reports Fiscal Q1 2022 Financials: $2.0 Million In Revenue

KetamineOne Capital (NEO: MEDI) released this morning its financial reports for the fiscal quarter ended October...

Thursday, December 16, 2021, 11:49:00 AM

KetamineOne Brings Scent-Enabled Virtual Reality To Psychedelic Therapy

KetamineOne Capital (NEO: MEDI) appears to be taking a rather novel approach to psychedelic treatments....

Wednesday, August 4, 2021, 08:12:47 AM